Groot, M.

patient hba 1c measurement diabetes therapy treatment study metformin 6–12 months hba 1c treatment onset measurement attainment cohort entry date monotherapy onset month persistence cohort t 2dm netherland baseline hba 1c 6–12 change erasmus mc baseline ogld users period association ogld use hba 1c goal mellitu practice guideline glucose-lowering drugs oad-therapy combination pharmo record non-persistent adherence population type 2 diabetes index date medication control level number 2 years disease glucose-lowering table 1 year reference 1.00 combination therapy study population insulin use episode novartis pharma ag percentage novarti insulin institute entry european result ogld treatment erasmu complication study cohort thiazolidinedione diabetes mellitus effect downloaded antidiabetic characteristic 08/29/11 informa pharmo institute t 2dm patients